Abstract-The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene has been associated with an increased risk of coronary heart disease, but whether it is a risk factor for underlying atherosclerosis remains unclear. Therefore, we examined to see whether the ACE gene deletion polymorphism was associated with carotid wall thickening and atherosclerotic plaque formation in a large randomly selected community population. A total of 1111 subjects, aged 27 to 77 years, with an equal male:female ratio and equal numbers in each age decile, were randomly selected from the Perth community population. Mean common carotid intima-medial wall thickness (IMT) and focal plaque formation were assessed by high-resolution B-mode ultrasound. 
O n the basis of the Etude Cas-Témoin de l'Infarctus du Myocarde study, Cambien et al 1 first reported in 1992 that a deletion polymorphism in the gene for the angiotensin-converting enzyme (ACE) was more frequent in patients with myocardial infarction (MI) than controls, especially among subjects formerly considered to be at low risk (low body-mass index and low plasma levels of ApoB). Subsequent case-control studies have not always agreed with this finding, although a recent meta-analysis 2 comprising 15 studies did support a significant (albeit weak) association between the ACE D allele and increased MI risk. In the same meta-analysis, 2 it was highlighted that all the case-control studies could be influenced by a mortality selection bias as cases were recruited at some time (variable) after the incident MI, and there was also a suggested publication bias toward smaller studies with positive results. It is noteworthy that the only prospective study, conducted in almost 3600 North American male physicians, found that the D allele of the ACE gene conferred no appreciable increase in risk of MI or ischemic heart disease. 3 Thus, it is still debated whether ACE insertion/deletion (I/D) gene polymorphism is associated with an increased cardiovascular risk.
The case for the ACE I/D polymorphism being a risk factor for coronary heart disease (CHD) would be stronger if it is shown that the D allele is associated with an increased risk of atherosclerosis. The mechanism(s) underlying such an association is unclear, but it is known that the level of circulating and probably tissue ACE activity are under strong genetic control. 4 -6 Higher circulating and tissue ACE activity is present in subjects with the D compared with I allele, 4 -6 although the I/D polymorphism is itself only a marker for the functional polymorphism that influences ACE levels. ACE catalyzes the conversion of angiotensin I to angiotensin II and the breakdown of bradykinin to kinin degradation products. Both angiotensin II and bradykinin are potent peptide hormones that play an important role in vascular wall homeostasis by opposing effects on vascular tone, vascular smooth muscle cell growth, and production of extracellular matrix. [7] [8] [9] [10] Thus, chronic exposure to high levels of circulating and tissue ACE may well predispose to vascular wall thickening and atherosclerosis.
The association between ACE I/D polymorphism and increased carotid intima-medial wall thickness (IMT) or carotid plaque formation has been examined in several relatively small and often selective population samples with heterogeneous findings. [11] [12] [13] [14] [15] [16] We therefore decided to test for the association of carotid IMT and ACE I/D polymorphism in the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). The latter consisted of 1111 male and female subjects, aged 27 to 77 years, randomly selected from the Perth community population, all of whom had high-resolution bilateral B-mode carotid ultrasound examination and ACE I/D gene polymorphism determined as part of a detailed risk factor assessment.
Methods

Subjects
Subjects were original participants in the 1989 Australian National Heart Foundation Perth Risk Factor Prevalence Survey. 17 This was a random electoral roll survey of 2000 people from the Perth, Western Australia, metropolitan area, with equal numbers of males and females and equal numbers of subjects in each age decile between 20 and 70 years. Repeat electoral roll and death record matching in May 1995 established a current address for 1807 living subjects. All of these were invited to attend our study clinic between June 1995 and December 1996, and 1111 subjects (61% of those eligible) agreed to participate. Subjects who had previous carotid artery surgery were excluded. The present study population was predominantly white with 90% of participants recording Australasia as their country of birth. Their age-adjusted prevalence of risk factors was similar to that reported for the entire 1989 cohort. 17 Written informed consent was obtained from all study participants. The study protocol was approved by the Institutional Ethics Committee of the University of Western Australia.
A self-administered questionnaire similar to that used by the 1989 Australian National Heart Foundation Risk Factor Prevalence Survey was used to record a history of hypertension, hyperlipidemia, diabetes, angina pectoris, MI, stroke, or a family history of premature-onset CHD by age 55 years in first-degree relatives. 17 Smoking lifetime exposure by pack-years was calculated. Anthropomorphic measurements and the lower of 2 resting sitting blood pressures (BPs), measured with a mercury column manometer, were recorded by a trained research nurse.
Laboratory Measurements
In all subjects, a fasting venous blood sample was obtained. Total cholesterol, HDL cholesterol, and triglyceride levels were determined enzymatically with a Hitachi 747 autoanalyzer. LDL cholesterol was calculated with the method of Friedewald et al. 18 Genomic DNA was extracted by the salt/phenol/chloroform method from the cells of the buffy coat. The I/D polymorphism of the ACE gene was detected by using PCR according to the method of Rigat et al. 19 Misclassification of ID to DD was checked by performing a second independent PCR amplification of DD samples, using an insertion specific primer 20 Plasma ACE activity was determined by using N-[3-(2 furyl)acryloyl]-L-phenylalanylglycylglycine substrate 21 and calibrated by the method of Buttery and Gee. 22 
Carotid Ultrasound
Bilateral carotid B-mode ultrasound was performed by 2 trained sonographers using a 7.5-MHz annular phased-array transducer on an Interspec (Apogee) CX 200 ultrasound machine. Scans were performed according to a standardized protocol similar to that used by Salonen et al. 23 The characteristic echo interfaces on the far wall of the distal common carotid artery was optimized and recorded on super VHS videotape along with an ECG lead for subsequent off-line analysis. A thorough search of the distal common carotid, carotid bulb, and internal and external carotid arteries was also made to determine the presence of focal plaque. Plaque was defined as a clearly identified area of focal increased thickness (Ն1 mm) of the intima-media layer.
The IMT was defined as the distance between the characteristic echoes from the lumen-intima and media-adventitia interfaces. 24 End-diastolic images were digitized and a semiautomated edgedetection software program used to identify leading-edge echointerface points from the far wall of the distal 1 cm of the common carotid artery. 25 Three end-diastolic images were analyzed from the right and left distal common carotid arteries at a site free of any discrete plaque, and measurements averaged to give the mean IMT. Repeat measurement of randomly selected scans revealed no significant variation in the IMT measurement obtained during any specific time period of the study. Quality control measures included repeat scans on a subset of 30 subjects on 2 separate occasions 7 to 10 days apart. The intraobserver coefficient of variability was 2.9% for sonographer 1 and 4.8% for sonographer 2. The interobserver coefficient of variability was 5.9%.
Statistical Analysis
Analysis was restricted to the 1106 subjects who had complete data including ACE I/D polymorphism and plasma ACE activity. Analysis was also performed on a subpopulation of 852 subjects defined as low risk based on a Framingham CHD risk score of Ͻ20. 26 This predicted an average CHD risk of Ͻ1.8% per year over 10 years. ANOVA was used to compare mean values between groups and if overall significance was demonstrated, intergroup differences were assessed by multiple range testing. Frequencies were compared by 2 analysis. Determinants of plasma ACE activity were assessed by multiple linear regression. Carotid mean IMT was treated as a continuous as well as a categorical variable with those above the 90th percentile of mean IMT (Ͼ0.8 mm) for the total cohort classified as having increased IMT. The relation of continuous risk factors with mean IMT was examined nonparametrically by using the Spearman rank correlation. The association of ACE activity and ACE genotype with thickened IMT or plaque was investigated by means of stepwise logistic regression analysis, considering potential confounding risk variables including age, sex, and other conventional risk factors. Risk variables were entered into the logistic regression analysis as the highest quartile versus other quartiles. The genotype effect was examined according to a dominant (DD/ID versus II), codominant (DD versus ID versus II), or recessive (DD versus ID/II) model. For multivariate risk predictors, the adjusted odds ratios are given with the 95% confidence intervals (CIs). Analysis was performed with SAS statistical software. 27 Statistical significance was taken as a 2-sided P value of Ͻ0.05. Results are expressed as meanϮSD values unless otherwise stated.
Results
In the total population, the frequency of the D allele was 55.2% and I allele 44.8%. The distribution of the genotypes conformed to the Hardy-Weinberg equilibrium (DD, 31.0%; ID, 48.4%; and II, 20.6%). The proportion of DD subjects did not change across age deciles from 27 to 77 years. No significant differences were found among the 3 genotypes with respect to sex, age, and conventional risk factors, including BP or a family history of premature CHD (Table 1) . Nor did we observe a significant difference among genotypes in the prevalence of a history of previous MI or stroke.
By Spearman rank correlation, plasma ACE activity was strongly associated with the ACE I/D polymorphism (r s ϭ0.53, PϽ0.0001). The ACE genotype affected plasma ACE activity levels in a codominant fashion with activity highest in DD, intermediate in ID, and lowest in II subjects in the overall population and the low-risk subpopulation (PϽ0.0001, ANOVA; Table 2 ). The ACE genotype, male sex, and history of hypertension were independent determinants of plasma ACE activity (total R 2 ϭ0.31, PϽ0.0001). History of hypertension was negatively correlated with plasma ACE activity, reflecting lower activity in those treated with ACE inhibitors. In the 842 subjects (76% of total population) without a history of hypertension, the genotype alone accounted for 33% of the total variance in measured ACE activity (R 2 ϭ0.33, PϽ0.0001). Among the ACE genotypes in the total population, there were no significant differences in the mean carotid IMT and prevalence of increased IMT or focal plaque (Table 2) . We calculated that the present study had Ͼ80% power at an ␣ level of 0.05 to detect a 5% difference in mean IMT thickness or a 30% difference in prevalence of focal plaque between the DD and other genotypes. The 852 subjects comprising the low-risk subpopulation had as expected a lower mean IMT than the rest of the population (0.67Ϯ0.12 versus 0.83Ϯ0.15 mm, PϽ0.0001), but again across the genotypes there were no significant differences in the mean IMT and prevalence of increased IMT or focal plaque (Table 2) .
On Spearman rank correlation, all the conventional continuous risk factors, but not plasma ACE activity or genotype, were significantly associated with mean IMT, as shown in Table 3 . Stepwise logistic regression analysis selected, in order, age, systolic BP, pack-years of smoking, LDL cholesterol level, waist/hip ratio, and history of antihypertensive treatment as multivariate predictors of thickened IMT in the total population, as shown in Table 4 . Sex was no longer a significant predictor once other risk variables were accounted for. For plaque, similar risk variables were selected with additional risk predictors being a history of vascular disease and diabetes mellitus ( Table 4 ). The plasma ACE activity and the D allele were not selected as predictors of thickened IMT or plaque formation, whether the allele was entered as a dominant, codominant, or recessive gene polymorphism. The adjusted odds ratio for thickened IMT in subjects with the DD versus ID/II genotypes was 0.9 (95% CI, 0.5 to 1.4); for plaque it was 0.9 (95% CI, 0.6 to 1.5) ( Table 4 ). There was also no association of D allele with thickened IMT or plaque in the conventional low-risk subpopulation, with similar adjusted odds ratios and CIs as those estimated for the total population.
Discussion
Our study demonstrated that the ACE I/D polymorphism is a strong determinant of plasma ACE activity, or, more correctly, is in tight linkage disequilibrium with a functional polymorphism that strongly influences circulating as well as tissue enzyme activity. 4 -6 This elevation may lead to increased risk of atherosclerosis by modulating the opposing effects of angiotensin II and kinins on endothelial function, smooth muscle cell proliferation, and extracellular matrix production in the vessel wall. [7] [8] [9] [10] Thus, it is postulated that subjects with the D allele may show increased carotid wall thickness, which is thought to represent an early phase of diffuse atherosclerosis. 24, 28 However, in this present study of a large randomly selected community population, we could find no association of the D allele with carotid mean IMT, or the prevalence of thickened IMT and carotid plaque formation. We also found no association between ACE genotypes and carotid wall thickness when examined in a subpopulation at conventionally low risk based on the Framingham CHD risk score.
A recent meta-analysis 2 that had included 15 studies supported a positive, although weak, association of the D allele with increased MI risk. However, it was noted that the study findings were heterogeneous, and that by contrast to the smaller (usually) positive case-control studies, the only large prospective study 3 did not show any increased MI risk with the D allele. It was believed that these study differences could well have been explained in many cases by an inadequate sample size, selection bias in patients or controls, and differences in age, ethnicity, and environmental background of populations studied. 2 The same limitations appear to apply to the small number of studies that have examined the association of ACE I/D polymorphism with carotid IMT, and reported similarly heterogeneous findings (summarized in Table 5 ). [11] [12] [13] [14] [15] [16] Four of these studies found a positive association, 11,14 -16 although this was only after a quarter of subjects on drug treatment were excluded from analysis in 1 small study 11 and only among nonsmokers in another study 16 ; 2 other studies 12, 13 showed no association of the D allele with carotid wall thickening or disease despite that it conferred an increased risk of lacunar stroke in 1 study. 13 None of the studies were able to demonstrate a relationship between the D allele and carotid plaque or stenosis.
The strength of the present study is that it was conducted in a large, randomly selected, community population, which included an equal male:female ratio, and subjects across a wide age range (27 to 77 years) with equal numbers in each age decile. The frequencies of the D and I alleles in our mainly white population are consistent with those reported in other similar populations. 2 There was not a decline in the frequency of the DD genotype with increasing age, as might be anticipated if it conferred an increased cardiovascular risk. As expected, the major conventional risk factors were found to be multivariate predictors of mean IMT and carotid plaque formation (Table 4) . However, the D allele was not found to be associated with either thickened IMT or carotid plaque formation, irrespective of whether it was considered a dominant, codominant, or recessive gene polymorphism. In fact, subjects with the DD versus other genotypes had an adjusted odds ratio for increased IMT and carotid plaque that was very near unity and with narrow CIs around this estimate. Cambien et al 1 made the original observation that the DD genotype was particularly associated with increased MI risk in those who were conventionally low risk. However, we found no association of D allele with increased IMT or carotid plaque in our subpopulation of subjects who had a predicted low CHD risk based on the Framingham risk score. We also found no difference in recorded systolic and diastolic BPs or history of hypertension among the 3 genotypes. Further, we observed no difference in the prevalence of a history of MI or stroke among the ACE genotypes, but it should be emphasized that our present study did not have the power to demonstrate or exclude an effect of ACE genotype on these vascular events given their low prevalence in this randomly selected community population. Our study should not be regarded as necessarily excluding an involvement of the renin-angiotensin system in the progression of atherosclerosis, and there is increasing experimental and clinical evidence for the vascular benefits of ACE inhibitor treatment. 9, 29, 30 However, the mechanism remains uncertain. 31 A pathogenetic role for other genetic mutations affecting the renin-angiotensin system is also possible. 31 However, this present study indicates that the ACE I/D polymorphism is not a useful marker of subjects at increased risk of atherosclerosis in a general community population. 
